Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that is a major cause of lower respiratory tract infection. hMPV causes repeat infections in children and adults and severe disease in older patients and individuals with underlying medical conditions. Mechanisms of hMPV immunity and pathogenesis are poorly understood and there are no licensed vaccines or therapeutics. The limited information available indicates that there are fundamental differences between hMPV and other paramyxoviruses, including respiratory syncytial virus. Accordingly, the central objective of the proposed research is to elucidate mechanisms of immunity to hMPV and define the contribution of host immune responses to disease. We propose three complementary specific aims to elucidate mechanisms of hMPV immunity and pathogenesis.
In Specific Aim 1, the role of antibody in protection and disease will be defined. B cell-deficient mice will be infected with hMPV and viral growth and lung pathology assessed following secondary infection. Passive serum transfer experiments will determine whether antibody is required for protection. The role of antibody- dependent cellular cytotoxicity in immunity and disease will be determined using NK cell-deficient mice.
In Specific Aim 2, the capacity of hMPV fusion (F) protein to mediate protection against reinfection will be determined. Mice will be immunized with F protein and challenged with engineered viruses encoding divergent F proteins. Immunized and challenged mice will be evaluated for respiratory disease and aberrant immune responses. These experiments will test the hypotheses that hMPV F protein vaccines will not be associated with enhanced disease and that hMPV F protein is capable of inducing broadly protective immunity.
In Specific Aim 3, the contribution of T cells to hMPV immunity and pathogenesis will be defined. Naive T cell-deficient mice will be infected with hMPV, and viral replication and lung pathology will be assessed. T-cell-deficient mice will be inoculated with hMPV, allowed to clear infection, and rechallenged to determine the contribution of T cells to protection against secondary infection and lung pathology. CTL epitope vaccination and adoptive transfer of cloned MHC class I-restricted epitope-specific CD8+ T cell lines will be used to determine whether virus-specific CD8+ T cells contribute to pathology. Results of the experiments proposed in this application will reveal mechanisms by which host immunity can lead to both resolution of infection and immunopathogenesis. These findings will advance knowledge of hMPV immunopathology, guide the development of hMPV therapeutics and vaccines, and have broad applicability to other respiratory viruses.

Public Health Relevance

The goal of this project is to define mechanisms of host immunity to human metapneumovirus (hMPV). hMPV is a recently discovered paramyxovirus that is a leading cause of lower respiratory tract disease in children worldwide. The knowledge gained from these experiments will be essential to develop safe and effective vaccines and therapeutics for HMPV. Further, the results of this work will increase our understanding of how interactions between respiratory viruses and the immune system contribute to disease and protection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI085062-03
Application #
8277445
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Kim, Sonnie
Project Start
2010-06-05
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
3
Fiscal Year
2012
Total Cost
$386,100
Indirect Cost
$138,600
Name
Vanderbilt University Medical Center
Department
Pediatrics
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Wen, Sherry C; Tollefson, Sharon J; Johnson, Monika et al. (2014) Acute clearance of human metapneumovirus occurs independently of natural killer cells. J Virol 88:10963-9
Cox, Reagan G; Erickson, John J; Hastings, Andrew K et al. (2014) Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model. J Virol 88:6368-79
Erickson, John J; Rogers, Meredith C; Hastings, Andrew K et al. (2014) Programmed death-1 impairs secondary effector lung CD8? T cells during respiratory virus reinfection. J Immunol 193:5108-17
Cox, Reagan G; Williams, John V (2013) Breaking in: human metapneumovirus fusion and entry. Viruses 5:192-210
Linder, Jodell E; Kraft, David C; Mohamed, Yassir et al. (2013) Human rhinovirus C: Age, season, and lower respiratory illness over the past 3 decades. J Allergy Clin Immunol 131:69-77.e1-6
Dunn, Sarah R; Ryder, Alex B; Tollefson, Sharon J et al. (2013) Seroepidemiologies of human metapneumovirus and respiratory syncytial virus in young children, determined with a new recombinant fusion protein enzyme-linked immunosorbent assay. Clin Vaccine Immunol 20:1654-6
Edwards, Kathryn M; Zhu, Yuwei; Griffin, Marie R et al. (2013) Burden of human metapneumovirus infection in young children. N Engl J Med 368:633-43
Yang, Chin-Fen; Wang, Chiaoyin K; Tollefson, Sharon J et al. (2013) Human metapneumovirus G protein is highly conserved within but not between genetic lineages. Arch Virol 158:1245-52
Miller, E Kathryn; Gebretsadik, Tebeb; Carroll, Kecia N et al. (2013) Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J 32:950-5
Shaikh, Fyza Y; Cox, Reagan G; Lifland, Aaron W et al. (2012) A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles. MBio 3:

Showing the most recent 10 out of 13 publications